GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » Long-Term Debt

United Therapeutics (STU:UTH) Long-Term Debt : €184 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is United Therapeutics Long-Term Debt?

United Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2024 was €184 Mil.

United Therapeutics's quarterly Long-Term Debt declined from Sep. 2023 (€469 Mil) to Dec. 2023 (€275 Mil) and declined from Dec. 2023 (€275 Mil) to Mar. 2024 (€184 Mil).

United Therapeutics's annual Long-Term Debt increased from Dec. 2021 (€708 Mil) to Dec. 2022 (€755 Mil) but then declined from Dec. 2022 (€755 Mil) to Dec. 2023 (€275 Mil).

United Therapeutics Long-Term Debt Historical Data

The historical data trend for United Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Long-Term Debt Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 540.00 657.60 708.00 755.20 275.10

United Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 747.20 738.40 468.50 275.10 184.00

United Therapeutics  (STU:UTH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

United Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (STU:UTH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » Long-Term Debt
Comparable Companies
INCY TECH SRPT RPRX ROIV LEGN VKTX CERE ASND EXEL OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
UTHR:USA
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
Website
https://www.unither.com
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (STU:UTH) Headlines

No Headlines